Skip to content
Comparison

CJC-1295 vs MK-677 (Ibutamoren)

CJC-1295 and MK-677 (Ibutamoren) are commonly compared for injectable GHRH analog versus oral ghrelin agonist. CJC-1295 is usually favored for pulse-oriented injectable control, while MK-677 (Ibutamoren) is often preferred for oral convenience and adherence simplicity. This head-to-head analysis focuses on mechanism, trial outcomes, dosing context, evidence quality, regulatory status, and practical decision points for safer YMYL decision-making.

4.3(112 ratings)

Quick Answer

For injectable GHRH analog versus oral ghrelin agonist, the better choice depends on your primary endpoint. CJC-1295 is stronger when the priority is users comfortable with injection-based optimization. MK-677 (Ibutamoren) is stronger when the priority is users prioritizing convenience and no injections. Use evidence grade, dose intensity, access constraints, and tolerability profile to match therapy to the patient profile rather than choosing by hype alone.

Head-to-Head Comparison

CriteriaCJC-1295MK-677 (Ibutamoren)
Primary mechanismModified GHRH analog supporting endogenous GH releaseOral ghrelin-receptor agonist GH secretagogue
Strongest clinical signalClinically meaningful GH and IGF-1 increasesRaises GH/IGF-1 with oral convenience
Typical dosing context100-300 mcg multiple times weekly or daily depending formulation10-25 mg once daily
AdministrationSubcutaneous injectionOral daily
Evidence quality gradeModerate, with notable pharmacokinetic studiesModerate human data in aging/body composition contexts
Regulatory statusNot FDA-approvedInvestigational, not FDA-approved
Side-effect burdenGenerally manageable side effectsAppetite, edema, and insulin-resistance concerns
Cost/access contextModerate program costOften lower cost than injectable GH pathways
Best candidate profileGHRH-driven GH optimization strategiesUsers valuing oral administration over injections
Main limitationProtocol complexity varies by DAC vs no-DAC choiceMetabolic side effects may limit long-term use
Best use case in this comparisonusers comfortable with injection-based optimizationusers prioritizing convenience and no injections

When to Choose Each

Choose CJC-1295

Best for users comfortable with injection-based optimization.

Choose MK-677 (Ibutamoren)

Best for users prioritizing convenience and no injections.

Verdict

If the main goal is users comfortable with injection-based optimization, CJC-1295 is usually the better first-line choice. If the main goal is users prioritizing convenience and no injections, MK-677 (Ibutamoren) is typically the better fit. Reassess outcomes at 8-16 weeks with objective metrics, then adjust only when response, safety, or adherence data justify it. In high-risk populations, physician-guided personalization matters more than any generic ranking.

References

  1. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults (2006) — PubMed
  2. A synthetic GH secretagogue (MK-677) and a GHRH analog (CJC-1295) act synergistically to promote GH release in humans (2008) — PubMed
  3. Growth hormone-releasing hormone analogs: chemistry and pharmacology (1999) — PubMed
  4. Dipeptidyl peptidase IV resistant analogues of growth hormone-releasing hormone (2005) — PubMed

Compare Telehealth Providers

Find the right provider for your peptide therapy needs

Hims & Hers

Most Popular
4.3

Starting at $199/mo

Hims & Hers is a leading telehealth platform offering physician-supervised GLP-1 weight loss programs including compounded semaglutide and tirzepatide. Board-certified providers, async or video consults, and medication shipped to your door.

✓Large, established platform with strong physician network
✓Compounded semaglutide available where branded shortages exist
✓Easy async consult — no video call required
✗Does not offer a wide range of peptides beyond GLP-1s
✗Pricing is on the higher end for GLP-1 programs

Henry Meds

Most Peptides
4.2

Starting at $249/mo

Henry Meds is a telehealth provider specializing in hormone optimization and peptide therapy. Beyond GLP-1 weight loss, Henry Meds offers testosterone replacement therapy, growth hormone peptides, and other advanced hormonal protocols managed by licensed physicians.

✓Broadest peptide therapy menu of any major telehealth provider
✓Growth hormone peptides (sermorelin, ipamorelin, CJC-1295) available
✓Repair peptides including BPC-157 and TB-500
✗Higher starting price due to comprehensive programs
✗More complex onboarding including lab work requirements

Ro Body

Best Value
4.1

Starting at $149/mo

Ro Body is a telehealth weight management program powered by GLP-1 medications. Ro connects patients with licensed providers who prescribe compounded semaglutide or branded GLP-1 therapies depending on eligibility, paired with behavioral coaching.

✓Competitive pricing starting at $149/mo
✓Dedicated health coach included in program
✓Strong clinical protocols with lab-work integration
✗Narrower peptide offering — GLP-1s only
✗Video consult required for initial visit

Calibrate

4.0

Starting at $199/mo

Calibrate is a metabolic health company offering a one-year GLP-1 program built around four pillars: food, sleep, exercise, and emotional health. Calibrate works with insurance to cover medication costs and provides extensive behavioral coaching alongside prescriptions.

✓Insurance navigation support for medication coverage
✓Evidence-based one-year program with structured milestones
✓Four-pillar lifestyle coaching (food, sleep, exercise, emotional health)
✗Annual program commitment required
✗Primarily focused on GLP-1s — no broader peptide therapy

Found

3.9

Starting at $129/mo

Found is a weight management telehealth platform that combines GLP-1 medications with behavioral coaching and a supportive community. Found emphasizes a whole-person approach, pairing pharmacological treatment with lifestyle intervention for sustainable results.

✓One of the more affordable monthly program fees
✓Strong community and peer support features
✓Certified health coaches with regular check-ins
✗Medication billed separately from program fee — total cost can be higher
✗Limited peptide variety beyond standard GLP-1s

Sponsored · We may earn a commission. Learn more · Updated February 2026

Henry MedsMost Peptides

Henry Meds is a telehealth provider specializing in hormone optimization and peptide therapy. Beyond GLP-1 weight loss, Henry Meds offers testosterone replacement therapy, growth hormone peptides, and other advanced hormonal protocols managed by licensed physicians.

From $249/moLearn More →

Sponsored · Affiliate Disclosure

Frequently Asked Questions

Which has stronger evidence for injectable GHRH analog versus oral ghrelin agonist — CJC-1295 or MK-677 (Ibutamoren)?
CJC-1295 is graded as moderate, with notable pharmacokinetic studies evidence in this context, while MK-677 (Ibutamoren) is graded as moderate human data in aging/body composition contexts. In practice, strength depends on whether you prioritize users comfortable with injection-based optimization or users prioritizing convenience and no injections. Favor the option with endpoint data closest to your primary goal, and avoid extrapolating beyond studied populations.
Can CJC-1295 and MK-677 (Ibutamoren) be combined or sequenced?
Sometimes, but only with clinician oversight. A common framework is to start with one agent, track objective response for 8-16 weeks, then switch or sequence if outcomes plateau or tolerability is poor. Combination protocols may increase both cost and adverse-effect complexity, so they should be justified by clear endpoint-based rationale.
What should be monitored before and during treatment?
Baseline assessment should include diagnosis confirmation, comorbidity risk, and contraindications. During therapy, monitor target outcomes (symptoms, body composition, labs), adverse effects, and adherence burden. For endocrine/metabolic strategies, periodic glucose, lipids, organ function, and indication-specific labs help keep risk proportional to expected benefit.

Explore next